URL copied Image Source : ANI
The first batch of 10,000 doses of 2DG medicine for curing COVID-19 patients would be launched early next week and will be given to patients, says DRDO officials.
At a time when country battles with the second wave of coronavirus, the first batch of 10,000 doses of 2DG medicine for curing COVID-19 patients would be launched early next week and will be given to patients, DRDO officials informed on Friday.
"The drug manufacturers are working on ramping up the production of the medicine for future use. The drug has been developed by a team of DRDO scientists including Dr Anant Narayan Bhatt," officials said.
Source:
ANI
New Delhi: Dr Sudhir Chandna, Institute of Nuclear Medicine and Allied Sciences (INMAS) scientist has said the recently approved anti-COVID-19 drug 2-deoxy-D-glucose (2-DG) is completely safe and will help patients recover faster.
"During clinical trials, it has yielded an effective result in curing patients infected with COVID-19. The medicine has gone through clinical trials on around 110 patients in the second phase. In the third phase, it was tried on 220 patients. It has shown better efficacy in phase two itself as compared to the standard care," Dr Chandna said.
"Recovery was two to three days faster for COVID-19 patients," he added.
Synopsis
Emergency approval for DRDO's anti-Covid drug 2-DG; trials claim reduced oxygen dependence, faster recovery
The Drug Controller General of India (DCGI) has given emergency use approval to 2-deoxy-D-glucose (2-DG), an anti-Covid drug developed by INMAS, a DRDO lab, in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad.
The drug is used as an adjunct therapy. Adjunctive therapy is administered along with primary treatment.
The clinical trials showed that the drug helps in faster recovery of those who have been hospitalised and also reduces need for supplemental oxygen.
The drug, which comes in a powdered form in a sachet, is taken orally by dissolving in water.
Story
Dr Reddy's to make, sell Eli Lilly's COVID-19 drug Baricitinib in India; 5th drugmaker to do so
Dr Reddy's has also tied up with Russian Direct Investment Fund, Russia's sovereign wealth fund that has bankrolled Sputnik V. It has also collaborated with DRDO to develop an anti-Covid drug, 2-deoxy-D-glucose (2-DG), which has also received approval from DCGI
BusinessToday.In | May 12, 2021 | Updated 11:31 IST
Baricitinib has received 'restricted emergency use approval' from the health ministry's central drugs standard control organisation
Dr Reddy's Laboratories has entered into a royalty-free, non-exclusive voluntary licencing agreement with US-based pharma major Eli Lilly and Company for the manufacture and sale of the drug, Baricitinib. Baricitinib has received 'restricted emergency use approval' from the health ministry's central drugs standard control organisation for use in combination with Remdesivir for treatment of suspected or confirmed COVID-19 patients who require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Healthcare workers transfer the body of a person who died from COVID-19, at a hospital in Kolkata, May 12, 2021. Photo: Reuters/Rupak De Chowdhuri
Mumbai: On May 1, the Drug Controller General of India (DCGI) approved a drug called 2-deoxy-d-glucose (2-DG) for emergency use among people with moderate and severe COVID-19, to help manage the disease.
This drug was jointly developed by researchers at the Institute of Nuclear Medicine and Allied Sciences, which falls under the Defence Research & Development Organisation (DRDO), and the pharmaceutical giant Dr Reddy’s Laboratories.
In line with the DCGI’s approval for favipiravir, itolizumab and Verafin, the approval for 2-DG is based on poor evidence.
Questions remain on DRDO’s COVID drug
Updated:
Updated:
May 12, 2021 08:33 IST
Experts flag lack of published data on performance in human trials, history of drug’s use in cancer cure
Share Article
AAA
On the frontline: A team of doctors and nurses at work in a COVID care centre near Ahmedabad.
Experts flag lack of published data on performance in human trials, history of drug’s use in cancer cure
A drug developed by the Defence Research and Development Organisation (DRDO) and approved by the Drug Controller General of India (DCGI) for “emergency use” in those with moderate to severe COVID may soon make its way to hospitals for treating moderate and severely ill patients, but independent experts say that from the information so far available, the drug's utility in COVID care has not been established.
DRDO’s anti-COVID drug to be available within a week
By News Desk| Updated: 12th May 2021 12:19 am IST
Hyderabad: A new anti-Covid oral drug developed by DRDO will be made available within one week to those who are in need, according to Dr Satish Reddy, Secretary Department of Defence Research and Development and Chairman (DRDO.
Speaking to Siasat.com here today, Chairman DRDO Satish Reddy informed that DRDO is making efforts to bring this new drug -2-deoxy-D-glucose (2DG) developed by the defence lab of the DRDO and this will be released by next week which will bring major relief to thousands of patients.
DRDO's anti-COVID drug to be available within a week siasat.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from siasat.com Daily Mail and Mail on Sunday newspapers.
May 10, 2021, 13:54 PM IST
New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that has been developed by Defence Research and Development Organisation (DRDO) and been given an emergency use nod by Drugs Controller General of India's (DCGI), was first studied by Patanjali researchers, claimed Acharya Balkrishna on Sunday (May 9, 2021).
A day after the DCGI granted permission for the Emergency Use of this drug as an adjunct therapy in moderate to severe COVID-19 patients, Acharya Balkrishna said, "We take immense pride that Patanjali has been the pioneer centre-stone for most of the researches conducted for COVID-19."
Balkrishna, MD of Patanjali Ayurved Ltd and co-founder of Patanjali Yogpeeth in Haridwar, also shared a picture of his research paper, co-authored with three other researchers.
India's drug regulator approves DRDO's anti-Covid oral drug for emergency use
AKIPRESS.COM - The drug speeds up recovery of hospitalised patients and reduces supplemental oxygen dependence, Business Standard reported.
India’s Defense Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad, has announced development of an anti-Covid-19 oral drug that speeds up recovery of hospitalised patients and reduces supplemental oxygen dependence.
“In the ongoing second Covid-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of Covid-19 patients,” stated India’s Ministry of Defense on May 8.